REDWOOD CITY, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Savant HWP, a privately held pharmaceutical development company focused on unmet medical needs in addiction medicine and selected other global health issues, announced today it has been selected to present at the Oxford University hosted Cavendish Global Health Impact Forum taking place Monday, November 10th to Thursday, November 13th at Oxford University in the United Kingdom.
"We are honored to present for a second time at this unique event, with our selection recognizing the recent advances we have made in our efforts to develop 18-MC as a treatment for many forms of drug addiction, as well as our program in Chagas Disease, a major cause of congestive heart failure in many areas of the world," said Stephen L. Hurst, JD, Savant HWP President and Chief Executive Officer. "We welcome the chance to interact with many of world's leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."
Mr. Hurst noted that since the company's presentation at the spring Cavendish Global Impact Forum in May 2014, Savant's South American development partner had initiated human clinical safety testing of 18-MC in healthy volunteers, with the experimental drug showing a positive safety profile in initial recipients.
The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
Michael Moffat, Cavendish co-founder and President explains, "With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Savant HWP's development programs positions them to make a major contribution to the treatment of many forms of drug addiction and abuse, as well as serious global health problems like Chagas Disease, an important cause of congestive heart failure."
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences." The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.
About Cavendish Global
Cavendish Global provides leading family offices and their foundations from around the world with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual impact investment, grant-giving and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative advisory and digital resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Forums take place three times each year and are hosted by leading institutions around the world. In May of 2014 the Cavendish Global Health Impact Forum was hosted at the United Nations Headquarters, Secretariat Building New York, The Rockefeller University and The New York Academy of Sciences. Following the Oxford University hosted Cavendish Forum in November of this year, the Cavendish community of family offices will next convene in the spring of 2015 in the United States. For more information: http://cavendishglobal.com
Contact:
Alex Charlton
President, Strategic Alliances, Cavendish Global
Direct Line: +1-917-576-1435
alex(dot)charlton(at)cavendishglobal(dot)com
About Savant HWP
Savant HWP, Inc., is a privately held pharmaceutical development company focused on unmet medical needs in addiction medicine and selected other global health issues including Chagas disease. The company's lead program is focused on the development of 18-MC, a novel compound that targets the dopamine "reward" pathway in the brain that drives pleasure-seeking behaviors associated with addiction, obesity and many forms of compulsive behavior.
For more information on Savant HWP, please visit our website at http://www.savanthwp.com.
Contact:
Stephen L. Hurst, JD
President and CEO
Savant HWP, Inc.
Ph: (650) 208-2454
Email: slhurst(at)savanthwp(dot)com
For Media
Joan E. Kureczka
Kureczka/Martin Associates
Ph: (415) 821 2413
Email: Joan(at)kureczka-martin(dot)com
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/11/prweb12305555.htm
CONTACT: Kureczka/Martin Associates
Joan Kureczka
joan@kureczka-martin.com
+1 (415) 821-2413
Help employers find you! Check out all the jobs and post your resume.
"We are honored to present for a second time at this unique event, with our selection recognizing the recent advances we have made in our efforts to develop 18-MC as a treatment for many forms of drug addiction, as well as our program in Chagas Disease, a major cause of congestive heart failure in many areas of the world," said Stephen L. Hurst, JD, Savant HWP President and Chief Executive Officer. "We welcome the chance to interact with many of world's leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."
Mr. Hurst noted that since the company's presentation at the spring Cavendish Global Impact Forum in May 2014, Savant's South American development partner had initiated human clinical safety testing of 18-MC in healthy volunteers, with the experimental drug showing a positive safety profile in initial recipients.
The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
Michael Moffat, Cavendish co-founder and President explains, "With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Savant HWP's development programs positions them to make a major contribution to the treatment of many forms of drug addiction and abuse, as well as serious global health problems like Chagas Disease, an important cause of congestive heart failure."
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences." The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.
About Cavendish Global
Cavendish Global provides leading family offices and their foundations from around the world with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual impact investment, grant-giving and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative advisory and digital resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Forums take place three times each year and are hosted by leading institutions around the world. In May of 2014 the Cavendish Global Health Impact Forum was hosted at the United Nations Headquarters, Secretariat Building New York, The Rockefeller University and The New York Academy of Sciences. Following the Oxford University hosted Cavendish Forum in November of this year, the Cavendish community of family offices will next convene in the spring of 2015 in the United States. For more information: http://cavendishglobal.com
Contact:
Alex Charlton
President, Strategic Alliances, Cavendish Global
Direct Line: +1-917-576-1435
alex(dot)charlton(at)cavendishglobal(dot)com
About Savant HWP
Savant HWP, Inc., is a privately held pharmaceutical development company focused on unmet medical needs in addiction medicine and selected other global health issues including Chagas disease. The company's lead program is focused on the development of 18-MC, a novel compound that targets the dopamine "reward" pathway in the brain that drives pleasure-seeking behaviors associated with addiction, obesity and many forms of compulsive behavior.
For more information on Savant HWP, please visit our website at http://www.savanthwp.com.
Contact:
Stephen L. Hurst, JD
President and CEO
Savant HWP, Inc.
Ph: (650) 208-2454
Email: slhurst(at)savanthwp(dot)com
For Media
Joan E. Kureczka
Kureczka/Martin Associates
Ph: (415) 821 2413
Email: Joan(at)kureczka-martin(dot)com
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/11/prweb12305555.htm
CONTACT: Kureczka/Martin Associates
Joan Kureczka
joan@kureczka-martin.com
+1 (415) 821-2413
Help employers find you! Check out all the jobs and post your resume.
